Plural Ring Hetero Atoms In The Bicyclo Ring System, Or Ring Nitrogen Is Shared By The Two Cyclos Of The Bicyclo Ring System Patents (Class 548/453)
  • Patent number: 10610517
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 7, 2020
    Assignees: Celgene International II SÀRL, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Patent number: 10312447
    Abstract: Objects of the present invention are to provide an organic semiconductor element in which carrier mobility is high, variation of mobility is suppressed, and temporal stability under high temperature and high humidity is excellent, and a manufacturing method thereof, to provide a novel compound suitable for an organic semiconductor, and to provide an organic semiconductor film in which mobility is high, variation of mobility is suppressed, and temporal stability under high temperature and high humidity is excellent, a manufacturing method thereof, and an organic semiconductor composition that can suitably form the organic semiconductor film. The organic semiconductor element according to the present invention is an organic semiconductor layer containing a compound having a constitutional repeating unit represented by Formula 1 and having a molecular weight of 2,000 or greater.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 4, 2019
    Assignee: FUJIFILM CORPORATION
    Inventors: Tetsu Kitamura, Yosuke Yamamoto, Fumiko Tamakuni, Yuta Shigenoi, Takashi Goto, Tetsuya Watanabe
  • Patent number: 10011814
    Abstract: Growth medium are disclosed for use in fermenting a marine microorganism. The medium comprise Potassium, Calcium, Strontium, Borate and Fluoride at specific concentrations. Alternatively, the growth medium comprises cobalt at specified concentrations or comprises vitamin B12 at specified concentrations. Methods of producing certain desired compound by fermentation of a marine microorganism are also disclosed.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: July 3, 2018
    Assignee: Celgene International II Sàrl
    Inventors: Kin Sing Lam, Ginger Tsueng
  • Patent number: 9828379
    Abstract: The invention provides pyrrolo-pyrrole carbamate and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, or pain, in a patient. The octahydropyrrolo pyrrole carbamates could be derived from hexafluoroisopropanol, N,N-disuccinimide and such. The activity of carbamates in MAGL, FAAH, and ABHD6 assays are also described.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: November 28, 2017
    Assignee: ABIDE THERAPEUTICS, INC.
    Inventors: Todd K. Jones, Justin S. Cisar, Cheryl A. Grice, Dong-Hui Wang, Olivia D. Weber
  • Patent number: 9670225
    Abstract: Various embodiments of the present invention are directed to compounds of the formula (I) or a pharmaceutically acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein X1, X2, X3, R1, R2, R11, and n are defined herein. These compounds are useful as inhibitors of HIV-1 protease and, as a result, are useful in the treatment of HIV infection.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: June 6, 2017
    Assignees: Purdue Research Foundation, National University Corporation Kumamoto University
    Inventors: Arun K. Ghosh, Venkateswara Rao Kalapala, Hiroaki Mitsuya
  • Patent number: 9630975
    Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: April 25, 2017
    Assignees: Tianjin Hemay Bio-Tech Co., Ltd., Tianjin Michele Sci-Tech Development Co., Ltd.
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
  • Patent number: 9605169
    Abstract: Aqueous green inkjet ink compositions are prepared from aqueous organic pigment dispersions for use in various inkjet printing methods. In particular, these methods provide a green image or expanded color gamut for other inkjet printed colors. The aqueous organic pigment dispersion contains a green copper phthalocyanine pigment and an azo-coupled ?-ketoamide pigment and an organic pigment dispersant. The weight ratio of the green copper phthalocyanine pigment to the azo-coupled ?-ketoamide pigment is from 1:1 to 10:1. The median particle diameter of each of the green copper phthalocyanine pigment and the azo-coupled ?-ketoamide pigment is less than 85 nm. At least 95% of the total particles of each of the green copper phthalocyanine pigment and the azo-coupled ?-ketoamide pigment have a particle diameter of less than 150 nm.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: March 28, 2017
    Assignee: EASTMAN KODAK COMPANY
    Inventors: Barbara Boland Lussier, Daniel Talbot Linehan
  • Patent number: 9481796
    Abstract: A method for producing a nanoparticle to separate a diketopyrrolopyrrole pigment includes separating an ?-type diketopyrrolopyrrole pigment nanoparticle having high crystallinity by carrying out separation of the diketopyrrolopyrrole pigment and crystal type transformation to the ?-type with substantially a single step. The ?-type diketopyrrolopyrrole pigment nanoparticle is separated by mixing a diketopyrrolopyrrole pigment solution having the diketopyrrolopyrrole pigment dissolved in a solvent and an alcohol solvent containing an alcohol compound solvent in a thin film fluid formed between at least two processing surfaces 1 and 2 arranged to be opposite to each other so as to be able to approach to and separate from each other, at least one of which rotates relative to the other. An acidic substance is contained in at least any one of the diketopyrrolopyrrole pigment solution and the alcohol solvent at this moment.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: November 1, 2016
    Assignee: M. TECHNIQUE CO., LTD.
    Inventor: Masakazu Enomura
  • Patent number: 9166168
    Abstract: An organic semiconductor polymer includes a moiety represented by the following Chemical Formula 1 and a heteroaromatic moiety having at least one of sulfur (S) and selenium (Se). In the Chemical Formula 1, R1, R2, R3a, R3b, R4a, R4b, R5a, and R5b, a1, a2, b1, and b2 are the same as described in the detailed description.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: October 20, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Hye Yeon Yang, Bang Lin Lee, Bon Won Koo, Joo Young Kim, Jeong Il Park, Eun Kyung Lee, Ji Youl Lee, Jong Won Chung, Ji Young Jung
  • Patent number: 9115144
    Abstract: Compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. Fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: August 25, 2015
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo Shimizu, Yusuke Onda, Masato Lizuka
  • Patent number: 9051330
    Abstract: The present invention provides novel dithiolopyrrolone compounds and their salts, which are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compositions comprising particularly useful types of dithiolopyrrolones, the salts thereof, and methods of using the compounds within such types, particularly in treating proliferative diseases such as cancer.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: June 9, 2015
    Assignee: Welichem Biotech Inc.
    Inventors: Genhui Chen, Jianxiong Li, John Webster, Bin Li
  • Publication number: 20150141479
    Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating moderate to severe pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
    Type: Application
    Filed: February 4, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150132887
    Abstract: The present invention relates to polymers comprising a repeating unit of the formula (I), and compounds of formula (VIII), or (IX), wherein Y, Y15, Y16 and Y17 are independently of each other a group of formula (I), and their use as organic semiconductor in organic electronic devices, especially in organic photovoltaics and photodiodes, or in a device containing a diode and/or an organic field effect transistor. The polymers and compounds according to the invention can have excellent solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers and compounds according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 14, 2015
    Applicant: BASF SE
    Inventors: Matthias Welker, Mathieu G.R. Turbiez, Natalia Chebotareva, Hans Juerg Kirner, Thomas Schaefer
  • Publication number: 20150126747
    Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
    Type: Application
    Filed: May 25, 2012
    Publication date: May 7, 2015
    Inventors: Allan Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
  • Patent number: 9018211
    Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: April 28, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Yuping Zhu, Aurash Shahripour, Haifeng Tang, Lihu Yang, Shawn P. Walsh, Nardos H. Teumelsan
  • Patent number: 9018397
    Abstract: The present invention relates to compounds of the formula I wherein the substituents are as defined in claim 1, and their use as organic semiconductor in organic devices, like diodes, organic field effect transistors and/or a solar cells. The compounds of the formula I have excellent solubility in organic solvents. High efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when said compounds are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 28, 2015
    Assignee: BASF SE
    Inventors: Zhimin Hao, Beat Schmidhalter, Jean-Luc Budry, Margherita Fontana, Matheiu G. R. Turbiez, Frank Bienewald, Mathias Duggeli, Oliver Frederic Aebischer, Pascal Hayoz, Marta Fondrodona Turon
  • Publication number: 20150110709
    Abstract: A method for producing a nanoparticle to separate a diketopyrrolopyrrole pigment includes separating an ?-type diketopyrrolopyrrole pigment nanoparticle having high crystallinity by carrying out separation of the diketopyrrolopyrrole pigment and crystal type transformation to the ?-type with substantially a single step. The ?-type diketopyrrolopyrrole pigment nanoparticle is separated by mixing a diketopyrrolopyrrole pigment solution having the diketopyrrolopyrrole pigment dissolved in a solvent and an alcohol solvent containing an alcohol compound solvent in a thin film fluid formed between at least two processing surfaces 1 and 2 arranged to be opposite to each other so as to be able to approach to and separate from each other, at least one of which rotates relative to the other. An acidic substance is contained in at least any one of the diketopyrrolopyrrole pigment solution and the alcohol solvent at this moment.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Applicant: M. Technique Co., Ltd.
    Inventor: Masakazu ENOMURA
  • Publication number: 20150087628
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: April 10, 2013
    Publication date: March 26, 2015
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Patent number: 8987265
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: March 24, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Paul Michael Scola
  • Publication number: 20150076418
    Abstract: The invention relates to novel conjugated polymers comprising in their backbone one or more divalent donor units, like for example benzo[1,2-b:4,5-b?]dithiophene-2,6-diyl (BDT), that are linked on both sides to an acceptor unit, to methods of preparing the polymers and educts or intermediates used in such preparation, to polymer blends, mixtures and formulations containing the polymers, to the use of the polymers, polymer blends, mixtures and formulations as semiconductors organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.
    Type: Application
    Filed: February 15, 2013
    Publication date: March 19, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Nicolas Blouin, Amy Phillips, Lana Nanson, Steven Tierney, Toby Cull, Priti Tiwana, Stephane Berney, Miguel Carrasco-Orozco, Frank Egon Meyer
  • Publication number: 20150080576
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the ?4?2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Anatoly Mazurov, Lan Miao, Yunde Xiao, Philip S. Hammond, Craig H. Miller, Srinivasa Rao Akireddy, Srinivasa V. Murthy, Regina C. Whitaker, Scott R. Breining, Matt S. Melvin
  • Publication number: 20150080382
    Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
    Type: Application
    Filed: June 24, 2014
    Publication date: March 19, 2015
    Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye
  • Publication number: 20150057420
    Abstract: A compound of formula (I), formula (II), or a combination thereof, and salts thereof is described. Each A may be independently an optionally substituted conjugated species or an optionally substituted aromatic species. Each R may be independently an optionally substituted C1-C40 linear alkyl chain, an optionally substituted branched alkyl chain, an optionally substituted alkyl chain containing heteroatoms, substituted alkyl chains, or H. Each R2 may be independently an optionally substituted C1-C40 linear alkyl chain, an optionally substituted branched alkyl chain, an optionally substituted alkyl chain containing heteroatoms, substituted alkyl chains, H, or part of a cyclic boronate ester with an other R2. Each n may be independently less than or equal to 3 and greater than or equal to 1. Each x may be independently less than or equal to 3.
    Type: Application
    Filed: August 15, 2014
    Publication date: February 26, 2015
    Inventors: Mingqian He, James Robert Matthews, Weijun Niu, Arthur Lawrence Wallace
  • Publication number: 20150057443
    Abstract: Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which they are attached, form C?O, for use in treating CNS disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Philip Huxley, Jonathan R. Heal, Richard S. Todd
  • Publication number: 20150041724
    Abstract: A substituent-eliminable diketopyrrolopyrrole derivative represented by the following formula (I) is provided. In the formula (I), R represents a substituted or unsubstituted alkyl group; X represents a substituted or unsubstituted alkyl group; Ar represents a substituted or unsubstituted aromatic group or a substituted or unsubstituted heteroaromatic group; and n represents an integer of from 1 to 4.
    Type: Application
    Filed: July 18, 2014
    Publication date: February 12, 2015
    Applicant: RICOH COMPANY, LTD.
    Inventors: Ryota Arai, Yoshiki YANAGAWA
  • Patent number: 8952178
    Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: February 10, 2015
    Assignees: Tianjin Hemay Bio-Tech Co., Ltd., Tianjin Michele Sci-Tech Development Co., Ltd.
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
  • Patent number: 8946445
    Abstract: The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 3, 2015
    Assignee: Nanjing Allgen Pharma Co., Ltd.
    Inventor: Zhaoyin Wang
  • Publication number: 20150028265
    Abstract: A conjugated polymer for electronic devices can include a repeated unit having the structure of formula (I)
    Type: Application
    Filed: July 23, 2014
    Publication date: January 29, 2015
    Inventors: Yang Yang, Letian Dou, Wei-Hsuan Chang
  • Patent number: 8927971
    Abstract: Disclosed are semiconducting compounds having one or more phthalimide units and/or one or more head-to-head (H-H) substituted biheteroaryl units. Such compounds can be monomeric, oligomeric, or polymeric, and can exhibit desirable electronic properties and possess processing advantages including solution?processability and/or good stability at ambient conditions.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: January 6, 2015
    Assignee: University of Kentucky Research Foundation
    Inventor: Mark D. Watson
  • Publication number: 20150005277
    Abstract: The invention is compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Application
    Filed: June 21, 2014
    Publication date: January 1, 2015
    Inventors: Zhiwei Wang, Yunhang Guo
  • Patent number: 8906911
    Abstract: Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: December 9, 2014
    Assignee: AbbVie Inc.
    Inventors: Michael D. Meyer, Xueqing Wang, Tao Guo, Robert Guo Ping Wei, Lijuan Jane Wang
  • Patent number: 8901087
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiang Chang, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, Feng Shi, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Patent number: 8889885
    Abstract: A method for producing a nanoparticle to separate a diketopyrrolopyrrole pigment includes separating an ?-type diketopyrrolopyrrole pigment nanoparticle having high crystallinity by carrying out separation of the diketopyrrolopyrrole pigment and crystal type transformation to the ?-type with substantially a single step. The ?-type diketopyrrolopyrrole pigment nanoparticle is separated by mixing a diketopyrrolopyrrole pigment solution having the diketopyrrolopyrrole pigment dissolved in a solvent and an alcohol solvent containing an alcohol compound solvent in a thin film fluid formed between at least two processing surfaces 1 and 2 arranged to be opposite to each other so as to be able to approach to and separate from each other, at least one of which rotates relative to the other. An acidic substance is contained in at least any one of the diketopyrrolopyrrole pigment solution and the alcohol solvent at this moment.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: November 18, 2014
    Assignee: M. Technique Co., Ltd.
    Inventor: Masakazu Enomura
  • Patent number: 8884018
    Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 11, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Narendra Bhalchandra Ambhaikar, Robert Hughes, Dennis James Hurley, Elaine Chungmin Lee, Benjamin Littler, Mehdi Numa, Stefanie Roeper, Urvi Sheth
  • Patent number: 8883889
    Abstract: The present invention relates to a process for the direct preparation of pyrrolo[3,4-c]pyrroles (DPPs) of the formula pigment compositions containing them and their use for coloring high molecular weight organic materials, such as plastics and paints. The obtained DPPs of the formula I possess a higher color strength, a higher chroma, a purer shade and a higher opacity versus corresponding commercially available DPPs.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: November 11, 2014
    Assignee: BASF SE
    Inventors: Vincent Ruffieux, Florence Modoux
  • Publication number: 20140326164
    Abstract: A method for preparing a surface modified organic pigment includes the steps of a) reacting the organic pigment in an aromatic hydrocarbon solvent with a surface modifying reagent to form a surface modified organic pigment; and b) washing and drying the surface modified organic pigment; wherein the surface modifying reagent is represented by Formula (I): wherein, X is selected from the group consisting of O, S and N—R3; Y is selected from the group consisting of —O and NR4; R1 to R4 are each independently selected from the group consisting of hydrogen, an alkyl group, an alkenyl group, an alkynyl group, a -aralkyl group, an alkaryl group, and an aryl group and s heteroaryl group; with the proviso that when Y—R1 is different from OH that at least one of R2 to R4 is substituted by at least one functional group having a pKa between 2.5 and 9.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 6, 2014
    Applicant: AGFA GRAPHICS NV
    Inventors: Johan Loccufier, Nicolas Vriamont, Paul Callant
  • Publication number: 20140329836
    Abstract: This invention provides compounds of formula (I): wherein R1, R2, G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: December 5, 2013
    Publication date: November 6, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • Patent number: 8877761
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: November 4, 2014
    Assignee: Pfizer Inc.
    Inventors: Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
  • Publication number: 20140309213
    Abstract: This invention relates to compounds of Formula I-VI having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH2)n1— and —(CH2)n2—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Application
    Filed: October 25, 2012
    Publication date: October 16, 2014
    Inventors: Shawn P. Walsh, Alexander Pasternak, Reynalda K. DeJesus, Haifeng Tang, Barbara Pio, Aurash Shahripour, Kevin M. Belyk, Harry R. Chobanian, Yan Guo, Jessica L. Frie, Zhi-Cai Shi, Helen Chen, Timothy A. Blizzard, Brian Cato
  • Publication number: 20140296537
    Abstract: Compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. Fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, or prodrugs thereof, or pharmaceutically acceptable salts thereof. In the formula (I), ring U represents C6-10 aryl or the like; R1 independently represents a hydrogen atom, a hydroxy group, C1-6 alkyl or the like; m represents an integral number from 1 to 2; ring Q represents 5-membered heteroaryl; n represents an integral number from 1 to 3; R2 independently represents a hydrogen atom, a halogen atom, C1-6 alkyl or the like.
    Type: Application
    Filed: August 23, 2012
    Publication date: October 2, 2014
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo Shimizu, Yusuke Onda, Masato Iizuka
  • Publication number: 20140288045
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu
  • Publication number: 20140288042
    Abstract: This invention relates to compounds of Formula I having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R represents a fused bicyclic or spirocyclic aliphatic diamine and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 25, 2014
    Inventors: Shawn P. Walsh, Alexander Pasternak, Zhi-Cai Shi, Brian Cato, Esther Y. Kim
  • Publication number: 20140271537
    Abstract: The present invention generally relates to deuterium-enriched aldehydes, compositions comprising deuterium-enriched aldehydes, and methods for slowing the rate of aldehyde autoxidation. In one aspect, the present invention provides a composition comprising a compound of structure 1: wherein: there are at least 6×1018 molecules of the aldehyde and Rx is hydrogen, wherein the deuterium isotope in Rx is in an amount greater than 0.10 percent of the hydrogen atoms present in Rx.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Inventor: Anthony W. Czarnik
  • Publication number: 20140275155
    Abstract: This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias GRAUERT, Ralf ANDERSKEWITZ, Marc GRUNDL, Thorsten OOST, Alexander PAUTSCH, Stefan PETERS
  • Publication number: 20140275093
    Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
  • Publication number: 20140275010
    Abstract: The present invention provides quaternary salts, such as those of Formula I: as well as the use thereof in methods of treatment for cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventors: Guo Zhu Zheng, Yuan Wang, Gregg F. Keany, Kenzo Arai, Kazunobu Kira, Xiang Liu, Nick Gearhart, Baudouin Gerard
  • Publication number: 20140256768
    Abstract: The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Inventor: Zhaoyin Wang
  • Publication number: 20140252278
    Abstract: Disclosed is a p-type organic semiconductive material that is easy to produce and that has a high planarity in its polymer skeleton, and also provides a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each having high photoelectric conversion efficiency and using the p-type organic semiconductive material. Specifically, the invention provides a bibenzo[b]furan compound having at least one constitutional unit represented by the following formula (1) or (2), as well as a photoelectric conversion material, a photoelectric conversion layer, a photoelectric conversion element, and an organic thin film solar cell each using that compound for a p-type organic semiconductive material.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 11, 2014
    Applicant: Adeka Corporation
    Inventors: Mineki Hasegawa, Toru Yano, Ryo Taniuchi
  • Publication number: 20140252341
    Abstract: Disclosed are a pyrrolo-pyrroledione-thiophenequinone compound as shown by formula I, a preparation process thereof and the use thereof as an organic semiconductor material. The preparation process for the compound of formula I comprises reacting NaH, an ?-bromine substituted pyrrolo-pyrroledione-thiophene oligomer as shown by formula II and malononitrile sodium salt, in the presence of catalytic Pd(PPh3)4, and then adding to the reaction system saturated bromine water to carry out an oxidation reaction, so as to obtain the compound of formula I. The compound of formula I has a good field effect performance, an electron mobility of above 0.1 cm2V?1s?1, an on/off current ratio up to 105, and is stable in air.
    Type: Application
    Filed: October 10, 2012
    Publication date: September 11, 2014
    Applicant: INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES
    Inventors: Yali Qiao, Jing Zhang, Wei Xu, Daoben Zhu
  • Patent number: 8822449
    Abstract: The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: September 2, 2014
    Assignee: Sanofi
    Inventors: Nils Rackelmann, Laurent Bialy, Heinrich Englert, Klaus Wirth, Petra Arndt, John Weston, Uwe Heinelt, Markus Follmann